ReShape announces shareholder approval of Vyome merger

ReShape Lifesciences (RSLS) announced that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol “HIND.” “Vyome’s vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor,” said Krishna Gupta, Chairman of Vyome. “We look forward to trading as a public company under the meaningful ticker symbol “HIND”, which we expect to be on India’s Independence Day – August 15. We have a very entrepreneurial and established board and management team, and we have a deep focus on creating value for our new and existing shareholders.” “We are grateful for the overwhelming support from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction offers a compelling opportunity for our shareholders as Vyome pursues its growth strategy as a Nasdaq-listed public company,” said Paul Hickey, Chief Executive Officer of ReShape.